— ACHIEVE-5 trial showed improved glycemic control with less insulin and no added hypoglycemia
by Gregory Laub, Senior Director, Video, MedPage Today
July 6, 2026
• 3 min read
At the American Diabetes Association annual meeting, results from the ACHIEVE-5 trial showed that adding oral orforglipron (Foundayo) to basal insulin significantly improved glycemic control, reduced body weight, and limited the need for insulin intensification without increasing hypoglycemia in adults with inadequately controlled type 2 diabetes.
